ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Soonmyung Paik, Chungyeul Kim, Norman Wolmark, None, HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer The New England Journal of Medicine. ,vol. 358, pp. 1409- 1411 ,(2008) , 10.1056/NEJMC0801440

Shizhen Emily Wang, Archana Narasanna, Marianela Perez-Torres, Bin Xiang, Frederick Y. Wu, Seungchan Yang, Graham Carpenter, Adi F. Gazdar, Senthil K. Muthuswamy, Carlos L. Arteaga, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. ,vol. 10, pp. 25- 38 ,(2006) , 10.1016/J.CCR.2006.05.023

Sarah B. Goldberg, Jeffrey G. Supko, Joel W. Neal, Alona Muzikansky, Subba Digumarthy, Panos Fidias, Jennifer S. Temel, Rebecca S. Heist, Alice T. Shaw, Patricia O. McCarthy, Thomas J. Lynch, Sreenath Sharma, Jeffrey E. Settleman, Lecia V. Sequist, A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 7, pp. 1602- 1608 ,(2012) , 10.1097/JTO.0B013E318262DE4A

Gabriele Schaefer, Lauric Haber, Lisa M. Crocker, Steven Shia, Lily Shao, Donald Dowbenko, Klara Totpal, Anne Wong, Chingwei V. Lee, Scott Stawicki, Robyn Clark, Carter Fields, Gail D. Lewis Phillips, Rodney A. Prell, Dimitry M. Danilenko, Yvonne Franke, Jean-Philippe Stephan, Jiyoung Hwang, Yan Wu, Jenny Bostrom, Mark X. Sliwkowski, Germaine Fuh, Charles Eigenbrot, A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell. ,vol. 20, pp. 472- 486 ,(2011) , 10.1016/J.CCR.2011.09.003

W. Xia, S. Bacus, P. Hegde, I. Husain, J. Strum, L. Liu, G. Paulazzo, L. Lyass, P. Trusk, J. Hill, J. Harris, N. L. Spector, A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 7795- 7800 ,(2006) , 10.1073/PNAS.0602468103

M Scaltriti, C Verma, M Guzman, J Jimenez, J L Parra, K Pedersen, D J Smith, S Landolfi, S Ramon y Cajal, J Arribas, J Baselga, Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene. ,vol. 28, pp. 803- 814 ,(2009) , 10.1038/ONC.2008.432

William Pao, Juliann Chmielecki, Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer Nature Reviews Cancer. ,vol. 10, pp. 760- 774 ,(2010) , 10.1038/NRC2947

Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, Carlos L. Arteaga, Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function Clinical Cancer Research. ,vol. 19, pp. 610- 619 ,(2013) , 10.1158/1078-0432.CCR-12-2024

Bin-Bing S. Zhou, Michael Peyton, Biao He, Changnian Liu, Luc Girard, Eian Caudler, Yvonne Lo, Frederic Baribaud, Iwao Mikami, Noemi Reguart, Gengjie Yang, Yanlong Li, Wenqing Yao, Kris Vaddi, Adi F. Gazdar, Steven M. Friedman, David M. Jablons, Robert C. Newton, Jordan S. Fridman, John D. Minna, Peggy A. Scherle, Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer Cancer Cell. ,vol. 10, pp. 39- 50 ,(2006) , 10.1016/J.CCR.2006.05.024

King Pan Ng, Axel M Hillmer, Charles T H Chuah, Wen Chun Juan, Tun Kiat Ko, Audrey S M Teo, Pramila N Ariyaratne, Naoto Takahashi, Kenichi Sawada, Yao Fei, Sheila Soh, Wah Heng Lee, John W J Huang, John C Allen, Xing Yi Woo, Niranjan Nagarajan, Vikrant Kumar, Anbupalam Thalamuthu, Wan Ting Poh, Ai Leen Ang, Hae Tha Mya, Gee Fung How, Li Yi Yang, Liang Piu Koh, Balram Chowbay, Chia-Tien Chang, Veera S Nadarajan, Wee Joo Chng, Hein Than, Lay Cheng Lim, Yeow Tee Goh, Shenli Zhang, Dianne Poh, Patrick Tan, Ju-Ee Seet, Mei-Kim Ang, Noan-Minh Chau, Quan-Sing Ng, Daniel S W Tan, Manabu Soda, Kazutoshi Isobe, Markus M Nöthen, Tien Y Wong, Atif Shahab, Xiaoan Ruan, Valère Cacheux-Rataboul, Wing-Kin Sung, Eng Huat Tan, Yasushi Yatabe, Hiroyuki Mano, Ross A Soo, Tan Min Chin, Wan-Teck Lim, Yijun Ruan, S Tiong Ong, A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nature Medicine. ,vol. 18, pp. 521- 528 ,(2012) , 10.1038/NM.2713